Fairpointe Capital LLC purchased a new stake in shares of Eyenovia Inc (NASDAQ:EYEN) in the second quarter, according to the company in its most recent filing with the SEC. The fund purchased 49,649 shares of the company’s stock, valued at approximately $313,000.

A number of other hedge funds also recently added to or reduced their stakes in EYEN. Uniplan Investment Counsel Inc. acquired a new position in Eyenovia during the 1st quarter valued at about $3,248,000. Millennium Management LLC acquired a new position in Eyenovia during the 1st quarter valued at about $2,525,000. Highbridge Capital Management LLC acquired a new position in Eyenovia during the 1st quarter valued at about $1,373,000. Finally, Sabby Management LLC acquired a new position in Eyenovia during the 1st quarter valued at about $908,000. Institutional investors and hedge funds own 12.28% of the company’s stock.

In other news, CEO Tsontcho Ianchulev bought 6,000 shares of the company’s stock in a transaction on Thursday, June 28th. The shares were purchased at an average price of $6.63 per share, with a total value of $39,780.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. 48.20% of the stock is owned by company insiders.

EYEN stock opened at $4.54 on Tuesday. Eyenovia Inc has a 52-week low of $4.70 and a 52-week high of $10.74.

Eyenovia (NASDAQ:EYEN) last released its quarterly earnings results on Tuesday, August 14th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.09. equities analysts anticipate that Eyenovia Inc will post -1.73 earnings per share for the current fiscal year.

Separately, Zacks Investment Research upgraded Eyenovia from a “hold” rating to a “buy” rating and set a $6.25 price target for the company in a research note on Friday, August 17th.

Eyenovia Profile

Eyenovia, Inc, a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia.

Featured Article: Day Trading

Want to see what other hedge funds are holding EYEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eyenovia Inc (NASDAQ:EYEN).

Institutional Ownership by Quarter for Eyenovia (NASDAQ:EYEN)

Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.